ACCS Hemorrhoid Treatment via Sustained Cellular Release

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current treatments for hemorrhoids often require surgical intervention and do not effectively prevent or accelerate healing, leading to a need for a more effective method to treat, prevent, and reduce inflammation associated with hemorrhoids.

Innovation Solution

Administration of novel cellular factor-containing solution compositions, specifically Amnion-derived Cellular Cytokine Solution (ACCS), which are formulated for topical application or as suppositories, providing sustained release of cellular factors to support healing and reduce inflammation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If surgical intervention is used to treat severe hemorrhoids, then the hemorrhoids are removed, but the treatment complexity and invasiveness increase

Engineering Contradiction:
Improveeffectiveness of hemorrhoid treatmentVSAvoidtreatment complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent introduces an intermediary substance (topical medication containing anti-inflammatory agents, vasoconstrictors, and anesthetics) that mediates between the hemorrhoid tissue and surgical intervention. This intermediary treatment reduces inflammation and swelling, thereby decreasing the need for complex surgical procedures while maintaining effective hemorrhoid management

Inventive Principle:
Principle #24Intermediary (Mediator)

Solution Approach 2:

The patent replaces mechanical surgical intervention with a chemical/pharmacological approach. Instead of using surgical tools to physically remove hemorrhoids, the invention uses topical medications with vasoconstrictors to chemically reduce blood flow and shrink hemorrhoidal tissue, thereby eliminating the need for complex mechanical surgery

Inventive Principle:
Principle #28Mechanics substitution (Replace mechanical system)

2Ease of operation

If conventional treatments are used for hemorrhoids, then some symptom relief is provided, but prevention and accelerated healing are not achieved

Engineering Contradiction:
Improvesimplicity of treatmentVSAvoideffectiveness in prevention and healing
Core Design Contradiction:
Ease of operationVSReliability

Solution Approach 1:

The patent changes the parameters of conventional topical treatments by incorporating multiple active ingredients with different functions (anti-inflammatory agents to reduce inflammation, vasoconstrictors to shrink tissue, and anesthetics for pain relief). This multi-parameter approach transforms simple symptom relief into a comprehensive treatment that addresses prevention, healing acceleration, and symptom management simultaneously

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent creates a universal topical medication formulation that performs multiple functions: preventing hemorrhoid development by reducing inflammation, accelerating healing of existing hemorrhoids, and providing symptom relief. This multi-functional approach replaces the need for multiple separate treatments with a single comprehensive solution

Inventive Principle:
Principle #6Universality (Multi-functionality)

Data Source

PatentUS8980251B2Methods for preventing and treating hemorrhoids
Publication Date: 2015.03.17 STEMNION

AI summary

The invention is directed to methods for treating hemorrhoids. The invention is also directed to methods for preventing hemorrhoids. The invention is further directed to reducing inflammation associated with hemorrhoids. The invention is further directed to methods for preventing hemorrhoids and/or treating hemorrhoids and/or reducing inflammation associated with hemorrhoids by administering to a subject suffering from such conditions, or at risk of developing such conditions, novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).